Home / Drugs & Interventions / Tapinarof / Clinical Trials Tapinarof Clinical Trials (2026): 19 Studies for Plaque Psoriasis & Atopic Dermatitis Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: June 16, 2026 .
19 Tapinarof clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Plaque Psoriasis & Atopic Dermatitis) and 4,920 total planned enrollment. 9 Phase 3 Tapinarof trials and 3 Phase 2, 4 Phase 4 are listed. 5 Tapinarof clinical trials are actively recruiting at 37 U.S. sites across 24 states. Most recent activity: NCT07352566 (Jun 2030).
Where to Participate: All Tapinarof Trial Sites in the U.S. (37 sites across 24 states) Every actively recruiting Tapinaroftrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
State Facility City Trial Map AL AllerVie Clinical Research Birmingham35209 NCT07265479 Map AR Dermatology Trial Associates Bryant72022 NCT07265479 Map CA Dermatology Research Associates Los Angeles90045 NCT07265479 Map CA Integrative Skin Science and Research Sacramento95815 NCT07265479 Map CA Allergy and Asthma Medical Group and Research Center San Diego92123 NCT07265479 Map CA Clinical Trials Research Institute Thousand Oaks91320 NCT07265479 Map CO Clarity Dermatology Castle Rock80109 NCT07265479 Map FL Skin Care Research, LLC. Boca Raton33486 NCT07265479 Map FL APEX Clinical Trials Jacksonville32256 NCT07265479 Map FL TruDerm Research Wellington33449 NCT07265479 Map GA Cleaver Medical Group Dermatology, Inc Cumming30040 NCT07265479 Map ID Ada West Research Meridian83646 NCT07265479 Map IL Endeavor Health Clinical Trials Center Skokie60077 NCT07265479 Map IN Dawes Fretzin Clinical Research Group, LLC Indianapolis46250 NCT07265479 Map IN Indiana University Department of Dermatology Indianapolis46202 NCT06561321 Map IN The Indiana Clinical Trials Center, PC Plainfield46168 NCT07265479 Map KY Equity Medical, LLC Bowling Green42104 NCT07265479 Map MD Lawrence J Green, MD LLC Rockville20850 NCT07265479 Map MI Oakland Hills Dermatology Auburn Hills48326 NCT07265479 Map MN Minnesota Clinical Study Center New Brighton55112 NCT07265479 Map MS SKY Integrative Medical Center Ridgeland39157 NCT07265479 Map MO MediSearch Clinical Trials Saint Joseph64506 NCT07265479 Map NV Skin Cancer and Dermatology Institute Reno89509 NCT07265479 Map NY Forest Hills Dermatology Group Kew Gardens11415 NCT07265479 Map NY Bobby Buka MD, PC New York10012 NCT07265479 Map NY Equity Medical, LLC The Bronx10455 NCT07265479 Map NC The University of North Carolina Dermatology and Skin Cancer Center Chapel Hill27516 NCT07265479 Map OH Dermatologists of Central States, LLC Fairborn45324 NCT07265479 Map OK Allergy Asthma and Clinical Research Center Oklahoma City73120 NCT07265479 Map OR Oregon Dermatology and Research Center Portland97210 NCT07265479 Map OR Oregon Health & Science University Portland97239 NCT07265479 Map SC Medical University of South Carolina Charleston29425 NCT07265479 Map SC National Allergy and Asthma Research, LLC. North Charleston29420 NCT07265479 Map TX The University of Texas Health Science Center at Houston Bellaire77401 NCT07265479 Map TX Dermatology Treatment and Research Center Dallas75230 NCT07265479 Map TX Stryde Research - Epiphany Dermatology Southlake76092 NCT07265479 Map WA Dermatology Specialists of Spokane Spokane99202 NCT07265479 Map
Tapinarof clinical trials at a glance: phase × recruitment status Phase recruiting active not recruiting enrolling by invitation completed not yet recruiting Total Early P1 1 1 P1 1 1 P2 1 2 3 P2/P3 1 1 P3 1 1 7 9 P4 3 1 4
Recruiting Tapinarof clinical trials (5) Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
NCT ID Title Phase Indication Enrollment Started NCT07352566 Utilization of a Microdevice for Psoriasis and Atopic Dermatitis P4 Psoriasis 10 Aug 2026 NCT07265479 Adoring A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisP3 Atopic Dermatitis 180 Dec 2025 NCT06561321 Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma P2 Palmoplantar Keratoderma 6 Oct 2024 NCT06661213 Tapinarof for Cutaneous Lupus Erythematosus Early P1 Cutaneous Lupus Erythematosus 10 Apr 2025 NCT05981118 Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) P2/P3 ICD10 Code L40.9 for Psoriasis 40 Jul 2024
Tapinarof clinical trials by indication Plaque Psoriasis (6) NCT Acronym Phase Status Title NCT05172726 — P3 active not recruiting Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects NCT07546214 — P1 completed A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. NCT04053387 — P3 completed Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) NCT03983980 — P3 completed Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) NCT03956355 — P3 completed Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) NCT04042103 — P2 completed Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
Atopic Dermatitis (5) NCT Acronym Phase Status Title NCT07265479 Adoring P3 recruiting A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis NCT05142774 — P3 completed Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis NCT05014568 — P3 completed Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults NCT05032859 DMVT-505-3102 P3 completed Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) NCT05186805 — P2 completed Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Psoriasis (4) NCT Acronym Phase Status Title NCT07352566 — P4 not yet recruiting Utilization of a Microdevice for Psoriasis and Atopic Dermatitis NCT06103695 — P4 completed Vtama in Psoriasis Patients Being Treated With Biologics. NCT05789576 — P4 completed A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region NCT05680740 — P4 completed A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
Cutaneous Lupus Erythematosus (1) NCT Acronym Phase Status Title NCT06661213 — Early P1 enrolling by invitation Tapinarof for Cutaneous Lupus Erythematosus
Plaque Type Psorisis (1) NCT Acronym Phase Status Title NCT06742957 — P3 completed Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
Palmoplantar Keratoderma (1) NCT Acronym Phase Status Title NCT06561321 — P2 recruiting Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma
ICD10 Code L40.9 for Psoriasis (1) NCT Acronym Phase Status Title NCT05981118 — P2/P3 enrolling by invitation Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
Tapinarof pivotal trial highlights (Phase 2/3/4) Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
All Tapinarof trials (19) Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
NCT ID Acronym Title Phase Status Enrollment Sponsor Started NCT07352566 Utilization of a Microdevice for Psoriasis and Atopic Dermatitis P4 not yet recruiting 10 University of California, San Francisco Aug 2026 NCT07265479 Adoring A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis P3 recruiting 180 Organon and Co Dec 2025 NCT06561321 Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma P2 recruiting 6 Indiana University Oct 2024 NCT06661213 Tapinarof for Cutaneous Lupus Erythematosus Early P1 enrolling by invitation 10 Northwestern University Apr 2025 NCT05981118 Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) P2/P3 enrolling by invitation 40 Wake Forest University Health Sciences Jul 2024 NCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects P3 active not recruiting 58 Organon and Co Dec 2021 NCT07546214 A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. P1 completed 575 Sun Pharmaceutical Industries, Inc. Oct 2025 NCT06742957 Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis P3 completed 560 Teva Pharmaceuticals USA Dec 2024 NCT05142774 Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis P3 completed 728 Organon and Co Oct 2021 NCT06103695 Vtama in Psoriasis Patients Being Treated With Biologics. P4 completed 30 Psoriasis Treatment Center of Central New Jersey Feb 2023 NCT05789576 A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region P4 completed 31 Organon and Co Mar 2023 NCT05680740 A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis P4 completed 34 Organon and Co Dec 2022 NCT05014568 Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults P3 completed 407 Organon and Co Sep 2021 NCT05032859 DMVT-505-3102 Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) P3 completed 406 Organon and Co Sep 2021 NCT05186805 Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis P2 completed 36 Organon and Co Nov 2021 NCT04053387 Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) P3 completed 763 Organon and Co Aug 2019 NCT03983980 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) P3 completed 515 Organon and Co Jun 2019 NCT03956355 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) P3 completed 510 Organon and Co May 2019 NCT04042103 Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis P2 completed 21 Organon and Co Jul 2019
Tapinarof clinical trials: frequently asked questions
How many Tapinarof clinical trials are there? 19 Tapinarof clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 13 are marked completed.
Are Tapinarof clinical trials recruiting in 2026? Yes — 4 Tapinarof trials are actively recruiting in 2026, with 37 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Tapinarof being studied for? Tapinarof is being studied for Plaque Psoriasis, Atopic Dermatitis, Psoriasis, Plaque Type Psorisis, Palmoplantar Keratoderma and 2 more. The trials are grouped by indication on this page.
What phase is Tapinarof in? Tapinarof clinical trials span 4 Phase 4, 9 Phase 3, 3 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tapinarof clinical trials? The lead sponsor across the most Tapinarof trials is Organon and Co, with 7 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information. Sources and methodology Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tapinarofas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed June 16, 2026 .
Related pages on Hipa.ai: